GRIN Therapeutics closes $140 million Series D financing, led by Angelini Pharma and Blackstone Life Sciences, to advance neurodevelopmental therapies.
GRIN Therapeutics closes $140 million Series D financing, led by Angelini Pharma and Blackstone Life Sciences, to advance neurodevelopmental therapies.
05/27/25, 3:01 PM
Location
new yorkMoney raised
$140 million
Industry
therapeutics
medical
biotechnology
health care
Round Type
series d
Investors
Blackstone Life Sciences, Angelini Pharma
GRIN Therapeutics has successfully closed a $140 million Series D funding round. This includes a strategic $65 million investment from Angelini Pharma and $75 million from Blackstone Life Sciences. The funding will support ongoing operations and a pivotal Phase 3 trial for the treatment of GRIN-related neurodevelopmental disorders. With this collaboration, GRIN aims to leverage Angelini Pharma's expertise to develop its investigational drug radiprodil.
Company Info
Location
new york, new york, united states
Additional Info
GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. Late last year, GRIN Therapeutics reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial, ClinicalTrials.gov NCT identifier: NCT05818943) evaluating radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function (GoF) variants, leading to the decision to advance to a global Phase 3 trial. The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences.